Weekly Genomic Health, Inc. (NASDAQ:GHDX) Ratings as of Dec 8, 2018

Genomic Health, Inc. (NASDAQ:GHDX) Corporate Logo
During 2018 Q2 the big money sentiment increased to 1.93. That’s change of 0.51, from 2018Q1’s 1.42. 7 investors sold all, 37 reduced holdings as Genomic Health, Inc. ratio increased. 42 rose stakes while 43 funds took stakes. Funds hold 31.18 million shares thus 0.39% more from 2018Q1’s 31.06 million shares.
Loomis Sayles And Com Lp, Massachusetts-based fund reported 489,354 shs. Wells Fargo And Mn holds 55,253 shs. Baker Bros Advisors Ltd Partnership invested 5.22% in Genomic Health, Inc. (NASDAQ:GHDX). 5,332 are held by Jpmorgan Chase And Co. Barclays Public Limited holds 0% of its capital in Genomic Health, Inc. (NASDAQ:GHDX) for 2,342 shs. Northwestern Mutual Wealth Co reported 22 shs or 0% of all its holdings. The California-based Globeflex Capital L P has invested 0.02% in Genomic Health, Inc. (NASDAQ:GHDX). Swiss Commercial Bank reported 36,300 shs stake. Moreover, Scout Investments has 0.09% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 78,697 shs. Element Management Ltd Liability Co reported 6,772 shs or 0.01% of all its holdings. 21,100 were accumulated by State Of Wisconsin Invest Board. Eam Limited Liability Co stated it has 69,993 shs. California Public Employees Retirement owns 54,552 shs or 0% of their US capital. Jacobs Levy Equity Management invested in 121,960 shs or 0.1% of the stock. Panagora Asset Mngmt reported 210,934 shs or 0.04% of all its holdings.

Genomic Health, Inc. registered $72.77 million net activity with 0 buys and 24 sales since June 11, 2018. Vaughn James J sold $255,545 worth of Genomic Health, Inc. (NASDAQ:GHDX) or 3,000 shs on Thursday, November 8. 5,500 shs were sold by Shak Steven, worth $272,554. The insider Cohen Fred E sold 10,000 shs worth $879,262. BAKER BROS. ADVISORS LP had sold 72,745 shs worth $6.23 million. Pla Frederic had sold 43,500 shs worth $3.69M. Cole G Bradley sold $679,027 worth of stock or 8,576 shs.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

In total 3 analysts cover Genomic Health (NASDAQ:GHDX). “Buy” rating has 1, “Sell” are 0, while 2 are “Hold”. 33% are bullish. 3 are the (NASDAQ:GHDX)’s analyst reports since June 13, 2018 according to StockzIntelligence Inc. On Friday, July 27 the firm has “Neutral” rating by PiperJaffray given. On Friday, August 3 the stock has “Buy” rating by Canaccord Genuity. On Wednesday, June 13 the firm has “Neutral” rating by Ladenburg Thalmann given. Listed here are Genomic Health, Inc. (NASDAQ:GHDX) PTs and latest ratings.

03/08/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $56 New Target: $62 Maintain
27/07/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $34 New Target: $50 Maintain
13/06/2018 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Neutral Old Target: $33 Downgrade

Ticker’s shares touched $72.9 during the last trading session after 3.44% change.Genomic Health, Inc. has 469,242 shares volume, 14.98% up from normal. GHDX is uptrending and has moved 100.94% since December 8, 2017. The stock outperformed the S&P 500 by 85.32%.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally.The company has $2.63 billion market cap. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.142.66 is the P/E ratio. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

For more Genomic Health, Inc. (NASDAQ:GHDX) news published recently go to: Nasdaq.com, Seekingalpha.com, Fool.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Genomic Health (GHDX) Hits a 52-Week High: What’s Driving It? – Nasdaq” published on September 12, 2018, “Canaccord bullish on medical diagnostic firms – Seeking Alpha” on September 14, 2018, “Here’s Why Genomic Health, Inc. Gained 14.8% in September – The Motley Fool” with a publish date: October 11, 2018, “Health Care Sector Update for 11/07/2018: FOMX,GHDX,PDLI,INGN – Nasdaq” and the last “The Daily Biotech Pulse: Foamix (NASDAQ:FOMX) Jumps on Data, Positive Results for Galapagos (NASDAQ:GLPG)-Gilead (NASDAQ:GILD)’s Rheumatoid Arthritis Drug, Bausch Health (NYSE:BHC) Trims Debt – Benzinga” with publication date: September 12, 2018.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.